# Vesper Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vesper-medical

- Industry: Medical Devices & Equipment
- Headquarters: Wayne, US
- Website: www.vespermedical.com
- Latest round: Series A (May 11, 2018)
- Investors on record: 2

## About

Vesper Medical, Inc. develops innovative medical devices focused on the treatment of deep venous disease, specifically targeting Chronic Venous Insufficiency (CVI) with advanced stent solutions.Founded in 2016, Vesper Medical, Inc. operates out of Wayne, US. The company specializes in advanced venous stent systems and has successfully raised a total of USD 37.00 mn across multiple funding rounds. The latest investment round occurred in December 2021, with participation from notable investors such as Gilde Healthcare Partners, New Enterprise Associates, Quaker Partners Management, and Vensana Capital. The CEO of the company is Bruce S.Vesper Medical, Inc. specializes in advanced medical devices aimed at treating deep venous disease, particularly focusing on Chronic Venous Insufficiency (CVI). Their flagship product is the Vesper DUO Venous Stent System®, which includes the DUO-HYBRID and DUO-EXTEND stents, designed to address complex anatomical challenges within the deep venous system. These stents are utilized in iliac and common femoral veins, effectively managing symptomatic obstructions. The company's products are marketed primarily to healthcare providers and hospitals across the United States and Europe, catering to a diverse patient base suffering from venous diseases.Vesper Medical generates revenue through the sale of its investigational venous stent systems, targeting hospitals and healthcare facilities. The revenue model follows a business-to-business (B2B) structure where healthcare providers directly purchase stents for clinical procedures. Positioned as specialized devices, the DUO-HYBRID and DUO-EXTEND stents address the needs of patients with CVI. As investigational products, they are often involved in clinical trials, contributing to the company’s research initiatives. Specific pricing plans for these products are typically determined through agreements established with healthcare entities during the procurement process.Vesper Medical aims to leverage its recent funding to enhance product development and market expansion. The company is focused on refining its existing stent systems and exploring the introduction of new products designed for treating diverse venous conditions, with expectations for future launches as they progress through regulatory pathways. Additionally, Vesper Medical plans to target expansion into new geographic regions, including other parts of Europe and Asia, by the end of 2023. In December 2021, Koninklijke Philips N.V. agreed to acquire Vesper Medical, marking a significant step in its growth trajectory.

## Funding rounds

- Series A, May 11, 2018 — New Enterprise Associates, Quaker Partners Management

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- Quaker Partners Management (https://capitalatlas.ai/funds/quaker-partners-management) — Series A